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SequestrectomyBRONJ has become a well-known, occasionally severe side effect of bisphosphonate therapy, as well as a clinical
problem. Although treatment recommendations exist, no standard therapy has yet been established for BRONJ.
Also, these recommendations identify several limitations that prevent clinicians from conﬁdently diagnosing
BRONJ. The aim of the present study was to establish a treatment approach in which all patients with exposed,
infected bone or intraoral/extraoral ﬁstulas were treated with sitaﬂoxacin (STFX). We examined 20 BRONJ pa-
tients, fourteenwith cancer and sixwith osteoporosis.We used the current updated deﬁnition of BRONJ (12), ex-
cept that we included patients who had shown symptoms for a minimum of only one month, rather than two
months. Thus half of our patients had infection with no exposed, necrotic bone in the oral cavity. We purposely
excluded all patients exhibiting no signs of infection (current Stages 0 and 1). In addition, each potentially caus-
ative organism was isolated from pus collected from an intraoral or extraoral ﬁstula in ten patients on their ﬁrst
visit to our department. 90% of the patients had received a course of treatment with common antibiotics. STFX
was administered to all patients. We then re-evaluated the lesion every other week, to determine whether epi-
thelialization was present. We recommended surgical treatment for cases without epithelialization within
4 weeks after the onset of administration of STFX even if bone was not exposed at the lesion. 19 of our 20
cases of Stages 2–3 BRONJ responded to 2–10 weeks of STFX treatment by entering either a remission or healed
phase. While surgery was done on thirteen cases, seven others reached such phases without surgery. Every pa-
tient had at least one bacterial species that showed resistance to common antibiotics. All species in all patients
were susceptible to STFX. Our results indicate that STFX, with or without minor surgery, gives a high probability
of controlling infection in BRONJ patients with persistent infection after use of common antibiotics, leading to re-
mission and/or complete healing in 95% of patients.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Bisphosphonates (BPs) have beenwidely, efﬁciently, and safely used
to treat osteoporosis, hypercalcemia of malignancy, bone metastasis of
solid malignant tumors, and Paget's disease of the bone [1]. However,
a relationship has been reported between the use of bisphosphonates
and osteonecrosis of the jaw (Bisphosphonate-Related Osteonecrosis
of the Jaw: BRONJ) [2]. BRONJ has become a well-known occasionally
severe side effect of bisphosphonate therapy as well as a clinical prob-
lem [3,4]. The clinical presentation of BRONJ generally includes gingival
ulcerationwith exposed necrotic bone in the oral cavity involving either
the maxilla or mandible that has persisted for at least 6–8 weeks. In
more severe cases, it may include inﬂamed, infected gingival tissues,, Tokyo, Japan. Fax:+81 422 42
. This is an open access article underintraoral or extraoral ﬁstulas, spontaneous severe pain, mobile teeth,
and/or pathological fractures [5–8].
However, though treatment recommendations exist [10,11,13], a
standard therapy has not yet been established for BRONJ. Ruggiero
et al. proposed guidelines for the diagnosis, staging, and management
of BRONJ in 2006 [9]. Thereafter, Ruggiero et al. and the American Asso-
ciation of Oral and Maxillofacial Surgeons reported their position on
BRONJ with an update of the previous classiﬁcation [10–12]. A position
paper was subsequently published by the Japanese Allied Task Force
Committee of BRONJ in Japan [13]. These studies established a working
deﬁnition for BRONJ that included the following three characteristics: 1
Current or previous treatmentwith a BP. 2 Exposed necrotic bone in the
jaw that persisted formore than 8weeks. 3 No history of radiation ther-
apy to the jaw.
Staging systems have also been established based on the ﬁndings of
these studies. BRONJ inwhichno apparent exposed bone area or speciﬁc
clinical ﬁndings or symptoms are detected has been classiﬁed as stage 0.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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not have soft tissue inﬂammation or infection. Stage 2 is characterized
by exposed bone with associated pain, adjacent or regional soft tissue
inﬂammatory swelling, or infection. Patients with Stage 3 have patho-
logical fractures, extraoral ﬁstulas, or radiographical ﬁndings of
osteolysis of the jaw in addition to the symptoms associated with
Stage 2. Though treatment recommendations exist [10–12,14] no deﬁn-
itive standard of care has been established for BRONJ and surgery was
previously reported as capable of exacerbating bone exposure [14–16].
These recommendations indicated that conservative therapies could
be applied to treat Stages 0 and 1 BRONJ and that surgical procedures
were unnecessary. Furthermore, these recommendations stated that
Stage 2 BRONJ patients were likely to beneﬁt from antibiotic therapy
to control or eliminate the infection. However, several limitations have
been identiﬁed in these recommendations that prevent clinicians from
conﬁdently diagnosing BRONJ. We previously encountered cases of
BRONJ (Stages 1 and 2) that deteriorated with conservative therapies
that included common antibiotics for Stage 2.
The aim of the present study was to establish a treatment approach
in which all patients with exposed, infected bone or intraoral/extraoral
ﬁstulas were treated with sitaﬂoxacin (STFX). After 4 weeks of STFX
treatment, surgery was used as needed, to remove necrotic hard and
soft tissue and prevent further permanent loss/alteration of soft and
hard tissue structures.
Materials and methods
Ethics
The present study was approved by the Institutional Review Board,
Kyorin University School of Medicine; all patients provided written in-
formed consent before participating in the study.
Patients
We examined 20 patients with BRONJ who presented to the Depart-
ment of Otorhinolaryngology and Oral Surgery, Kyorin Hospital, Tokyo,
Japan between April 2010 and April 2013. Ten patients had prostate
cancer, two had breast cancer, one had renal cell carcinoma, one had
multiple myeloma, four had primary osteoporosis, and two had GIOP
(glucocorticoid-induced osteoporosis) (Table 1).
The working deﬁnition of BRONJ used in the present study included
a more than 1-month history of severe jaw pain, discharge of pus, and
current or previous treatment with a BP in patients who presented
with or without necrotic bone exposure. The absence of malignancy in
the area surrounding the lesion and the absence of a history of radiation
therapy to the jaw was noted. Clinical data were recorded for each pa-
tient only after all examiners completely agreed with each other. In
this series, we excluded patients who exhibited no sign of infection
(current Stages 0 and 1). Some patients presented with symptoms of
paranasal sinusitis. Those symptoms included nasal obstruction and
congestion, purulent rhinorrhea, and facial pain or pressure with occa-
sional headache, and/or fever.
Sixteen of the twenty patients had already been given common
antibiotics for several weeks before visiting our department (except pa-
tients 6, 10, 13 and 15). Despite this antibiotic treatment, these patients'
symptoms still existed. In these 16 patients, we started STFX immedi-
ately. In patients 10 and 13, intraoral ﬁstula and exposed bonewere de-
tected at least 8 weeks before the patients' ﬁrst visit to our department
(e.g., Fig. 2). In addition, information of BP receiving for more than 6
months was known from the urology specialist. Therefore, we have di-
agnosed BRONJ with these ﬁndings and information. Since we already
recognized clinical ﬁndings of BRONJ at the ﬁrst visit, we started STFX
immediately without administration with common antibiotics in these
patients. Also, these patients had not been given common antibiotics
before visiting us. On the other hand, patients #6 and #15 both hadrecent mobile and infected tooth extractions in our department with
the usual method, that is, administration with common antibiotics for
1 week after extraction because we could not obtain BP receiving infor-
mation at this point. Despite treatment with common antibiotics for
7 days after tooth extraction, failure to heal twoweeks laterwas indicat-
ed when, sharp instruments could easily contact bone and there was
painful, swelling. Hence, we requested further information from pa-
tients and family about BP receiving, and thenwewere able to establish
a documented history of BP treatment. Four weeks later, we could
diagnose BRONJ, because the CT scan conﬁrmed the existence of
osteosclerosis without oral cavity bone exposure, and pus discharge
and intraoral ﬁstula were detected from alveolar soft tissue wound.
We then started STFX immediately. Computed tomography (CT) is com-
monly used as a diagnostic tool because of its accessibility for patients
and its ability to reveal the degree of osteosclerosis on the affected
site, which is visualized as the loss of contrast deﬁnition between the
cortical bone and the bone marrow space. If a suspicious oral lesion
with no exposed bone (e.g., Fig. 1a) was found in a patient with an
intraoral ﬁstula (IOF) or extraoral ﬁstula (EOF), a CT scan was done to
check for osteosclerosis, because osteosclerosis appears to characterize
early stages of BRONJ that may precede actual bone exposure. When
osteosclerosis was found in the bone underlying such a suspicious le-
sion, as in #6, STFX was started immediately.
Antimicrobial susceptibility testing
Each potentially causative organismwas isolated from pus collected
from an intraoral or extraoral ﬁstula in ten patients on their ﬁrst visit to
our department. These isolates were rapidly identiﬁed using the API 20
Strep [17] and Vitek anaerobe identiﬁcation card system (Sysmex
BioMerieux, Tokyo, Japan) [18]. Antimicrobial susceptibility testing of
the isolated bacteria to sitaﬂoxacin and the other antimicrobial agents
was performed according to the Clinical and Laboratory Standards Insti-
tute (CLSI) guidelines [19,20].
Treatment procedure
After 1–4 weeks of common antibiotic treatment, except in #10 and
#13, to whom no common antibiotics were given, STFX was adminis-
tered to all patients. We then re-evaluated the lesion every other
week, to determinewhether epithelializationwas present. Sharp instru-
ments could easily contact bone if the lesion was not epithelialized.
We recommended surgical treatment for thirteen patients where se-
questrum and necrotic soft and hard tissue remained for a period of
4 weeks after the administration of STFX, even if the bone was not ex-
posed deﬁnitively at the lesion. By contrast, in seven patients, sharp in-
struments could not contact bone, and no necrotic soft or hard tissue
remained to be removed 4 weeks after the onset of treatment with
STFX. Therefore, these seven cases were regarded as non-surgical cases.
Table 1 shows that STFX dosage varied from 1750 to 9100 mg (total
dose) and duration varied from 2 to 10weeks. STFXwas used orally and
accomplished on an outpatient basis.
In addition, 6 to 12 weeks was considered necessary from the initia-
tion of active treatment in order for patients to achieve a completely
healed state. We did necrotic bone resection and infected soft tissue
debridement with or without tooth extraction in all operative cases
(Table 1).
The term, healed, was used to describe complete disappearance of
exposed bone and the absence of infection in the jaw of an ONJ patient,
while remission, reﬂected the partial disappearance of exposed bone
with the absence of infection.
Results
We examined a total of 20 BRONJ patients (Table 1). We propose
that cases with an intra- or extraoral ﬁstula or maxillary sinus
Table 1
Demographic and clinical characteristics of ONJ patients.
BP CAB STFX
Case Age Gender Primary disease DBP (month) Dose Route Type Region of the jaw D (week) Treatment TD (mg) D (week) Outcome Signiﬁcant Findings BE IOF EOF
1 77 M Prostate cancer 27 4 mg/month IV Z L upper molar 3 STFX 5600 4 Remission RTE − + +*
2 85 M Prostate cancer 10 4 mg/month IV Z R upper anterior 2 STFX 2800 4 Healed PSUD − + −
3 75 M Prostate cancer 36 4 mg/month IV Z R lower, L upper molar 4 STFX, SE under LA 5600 4 Remission PSUD + − +*
4 78 M Prostate cancer 29 4 mg/month IV Z L upper molar 4 STFX, SE under LA 2800 4 Healed RTE − + −
5 70 M Prostate cancer 8 4 mg/month IV Z L upper, lower molar 2 STFX, SE under GA 9100 10 Healed RTE − + −
6 73 M Prostate cancer 24 4 mg/month IV Z L upper anterior 1** STFX, SE under LA 9800 9 Healed RTE − + −
7 69 M Prostate cancer 23 4 mg/month IV Z L upper, lower molar 2 STFX, SE under LA 5600 8 Healed RTE + + −
8 71 M Prostate cancer 5 4 mg/month IV Z R and L lower molar 1 STFX, SE, TE under GA 3500 5 Healed periodontitis + + −
9 77 M Prostate cancer 17 4 mg/month IV Z L upper anterior 2 STFX, SE under LA 5600 4 Healed PSUD − + −
10 76 M Prostate cancer 33 4 mg/month IV Z L lower, upper molar − STFX, SE under GA 5600 8 Worsening None noted + + −
11 49 F Breast cancer 60 4 mg/month IV Z R upper molar 2 STFX, SE under LA 5600 8 Healed None noted − + −
12 48 F Breast cancer 58 4 mg/month IV Z R upper molar 2 STFX, SE, TE under GA 5600 8 Healed periodontitis + − +*
13 67 M Renal cell carcinoma 6 4 mg/month IV Z R,L lower molar − STFX, SE, TE under GA 4200 6 Healed periodontitis + + −
14 29 M Multiple myeloma 18 4 mg/month IV Z R lower molar 2 STFX 5600 8 Healed periodontitis − + −
15 73 F Primary osteoporosis 24 35 mg/week Oral A L lower molar 1** STFX 3500 3 Healed RTE + − −
16 76 M GIOP-RP 96 35 mg/week Oral A R upper, L lower molar 2 STFX 2800 2 Remission fractured tooth − + −
17 76 F Primary osteoporosis 48 35 mg/week Oral A across the lower jaw 2 STFX 5600 4 Remission PSUD + + −
18 70 F GIOP-RA 60 35 mg/week Oral A L upper molar 2 STFX, SE, TE under LA 1750 5 Healed periodontitis − + +*
19 84 F Primary osteoporosis 24 35 mg/wk. Oral A L lower molar 4 STFX 6300 8 Healed periodontitis − + +
20 84 F Primary osteoporosis 12 50 mg/month Oral M R, L lower anterior 4 STFX, SE, TE under LA 6300 8 Healed periodontitis − − +
Abbreviations; A: alendronate, BE: bone exposure, CAB: administration of common antibiotics, D: duration, DBP: duration of BP, EOF: extraoral ﬁstula, GA: General anesthesia, GIOP: glucocorticoid-induced osteoporosis, IOF: intraoral ﬁstula, IV: in-
travenous, L: left side, LA: Local anesthesia, M:minodronate, PSUD: pressure sore under dentures, R: right side, RA: rheumatoid arthritis, RP: relapsing polychondritis, RTE: recent tooth extraction, SE: sequestrectomy, STFX: administration of
sitaﬂoxacin, TD: total dose, TE: tooth extraction, Z: zoledronate, *:affected maxillary sinuses, **administration of CAB from our department.
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Fig. 1. Patient number 6: non-exposed bone case. a: The maxillary left cuspid was extracted 6 weeks later. An intraoral ﬁstula (arrow head) was detected. The administration of
100 mg per day STFX was started. b: Following necrotic bone resection under local anesthesia after the administration of 100 mg per day of STFX for 3 weeks. c: Completely
healed surgical wound 3 months after surgery. d: CT scan showing the failed healing of the extracted wound (at the same time as the photo in a).
220 T. Ikeda et al. / Bone 73 (2015) 217–222involvementwithout exposed oral cavity bone, as in patients 1, 2, 4, 5, 6,
9, 11, 14, 16, 18, 19, and 20, should be deﬁned as Stage 3 BRONJ, rather
than Stage 0 BRONJ, because an active infection and a ﬁstula are clearly
involved. Patients 1, 3, 12 and 18, exhibited symptoms of paranasal si-
nusitis. Such patients seem likely to beneﬁt from antibiotic therapy
that would not be given to them if they were diagnosed as Stage 0.
Bacterial specieswere counted in patients 1, 3, 6, 14, 15, 16, 17, 18, 19
and 20. The following species were detected (number of patients
in parenthesis); Bacteroides capillosus, Corynebacterium species,
Fusobacterium nucleatum (2),Gemella species (2), Klebsiella pneumoniae,
Parvimonas micra (2), Parvimonas micra (Peptostreptococcus micros)a
b
Fig. 2. Patient number 13: exposed bone case. Exposed necrotic bone on the lingual plate in th
cortical bone separation (sequestrum) of the right side of the mandible. Axial section image. c:
d: A tightly sutured wound after the causative teeth were extracted and sequestrectomy wa
necrotic bone was indicated by the arrows in a and c.(3), Peptostreptococcus anaerobius, Porphyromonas asaccharolytica,
Porphyromonas endodontalis, Porphyromonas gingivalis, Prevotella buccae
(2), Prevotella disiens, Prevotella intermedia (2), Prevotella species,
Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus
agalactiae, Streptococcus anginosus (4), Streptococcus constellatus (5),
Streptococcus mitis (4), and α-hemolytic Streptococcus. The clinical states
of cancer- or non-cancer-BRONJ were also not markedly different. Every
patient had at least one species that showed resistance to common anti-
biotics. All species in all patients were susceptible to STFX.
Infection disappeared from the area of the BRONJ lesion within
10 weeks of STFX treatment in 19 of 20 cases. While surgery wasc
d
e
f
e right mandibular molar region on the ﬁrst visit (a: mirror image). b: CT showing lingual
The right side of mandible after the administration of 100 mg per day of STFX for 3 weeks.
s performed (e). Completely healed surgical wound 6 months after surgery (f). Exposed
221T. Ikeda et al. / Bone 73 (2015) 217–222done on 13 cases, 7 others reached such phase without surgery. Epithe-
lialization and improvement actually occurred in 12 of 13 surgical cases
and all non-surgical cases.Discussion
BP can accumulate in the bone and inhibit osteoclast-mediated
bone resorption, thereby reducing bone turnover at the cellular and
molecular levels [21,22]. Thus, BRONJ patients, like all patients taking
therapeutic doses of BPs for treatment of cancer and osteoporosis, are
characterized by low levels of osteoclastic activity and bone remodeling
in thewhole skeleton. However, 90% of our BRONJ patients had a unique
signiﬁcant abnormal ﬁnding in the maxilla or mandible (e.g., recent
tooth extraction, pressure sore under denture, periodontitis or fracture
tooth), suggesting the possibility that local dental factors may combine
with the low levels of osteoclast activity to make an environment that
favors the development of BRONJ.
Previous studies avoided active jaw surgery in patients who were
being or had been previously treated with BPs [23–27]. However, the
majority of our patients (70%) did not have dental surgical injuries;
therefore, BRONJmay have been related to other factors such as asymp-
tomatic periodontitis and pressure sores under dentures. The beneﬁts of
BPs outweigh theirminor side effects; they save the lives of osteoporotic
patients by preventing hip fractures and extend the healthy life spans of
cancer patients by preventing bonemetastases and stabilizing the skel-
eton, thereby allowing cancer patients to endure stronger treatments
that may eventually cure them. On the other hand, the incidence of
BRONJ is very low. Physicians need to ensure that patients understand
the life-saving effects of BPs and that they obtain regular dental care
in order to maintain optimal dental health while receiving BPs.
In this series, all patients exhibited clinical evidence of infection on
their ﬁrst visit. However, we could not deﬁnitively conﬁrm when bone
became exposed and could only obtain this information from a medical
interview. We previously encountered cases of BRONJ that deteriorated
with conservative therapies and/or treatments with common antibi-
otics. If the lesion did not heal within 4 weeks of conservative therapies
and/or the administration of common antibiotics, treatment with a
powerful ﬂuoroquinolone antibiotic, sitaﬂoxacin was initiated as soon
as possible to prevent jaw resection, pathological fractures or sinus
tract complications.
Therefore, our approach to therapeutic strategies for BRONJ differed
from those reported previously [10,11,13–16] because we considered
early treatment to be important; we successfully treated Stage 2 or 3
BRONJ patients with or without surgery following the administration
of STFX.
A signiﬁcant result of our study was that we could not assign ten
cases to any of the published stages [10–11]. Though these cases had
no exposed necrotic bone suggesting Stage 0, they had purulent dis-
charge from intraoral or extraoral ﬁstulas and severe pain, suggesting
active infection and Stage 3 (Fig. 1). Recently updated staging guidelines
have also identiﬁed such cases (12). We agree that BRONJ cases that
display intraoral or extraoral ﬁstulas or maxillary sinus involvement
should be deﬁned as Stage 3, even when exposed necrotic bone in the
oral cavity cannot be found. The importance of this for our series is
clear, as half our cases met these criteria. In addition, placing such
cases in Stage 3 makes immediate antibiotic therapy appropriate, even
according to older guidelines.
Other recent studies reported that bone exposure was not always
observed in a subset of cases that otherwise exhibited the characteristic
hallmarks of BRONJ [28–31]. In this series, four patients (#1, #3, #12
and #18) with Stage 2 or 3 BRONJ demonstrated paranasal sinusitis.
Like other investigators [28], we conclude that paranasal sinusitis may
be related tomaxillary BRONJ. Thus, maxillary BRONJ should be consid-
ered in the differential diagnosis when persistent paranasal sinusitis is
found in a patient taking BPs.Although Stage 2 or 3 BRONJ is characterized by active infection, a
deﬁnitive treatment procedurewith speciﬁc antibiotics had not been re-
ported. Antimicrobial susceptibility testing of isolated bacteria to STFX
and other antimicrobial agents was performed in ten patients. The re-
sults obtained indicated that at least one of the organisms in each pa-
tient was resistant to common antibiotics. 19 of our 20 cases of Stages
2–3 BRONJ responded to 2–10 weeks of STFX treatment by entering ei-
ther a remission or healed phase (Table 1). While minor surgery was
done on thirteen caseswith a favorable response in twelve, seven others
reached such phaseswithout surgery.We speculate that the high rate of
success for STFX is because it kills quinolone-resistant bacteria.
Computed tomography (CT) can be useful for BRONJ because of
its ability to reveal osteosclerosis that appears as a loss of contrast
deﬁnition between the cortical bone and the bone marrow space
(Fig. 1d). Osteosclerosis may characterize the early stages of BRONJ
and precede the occurrence of bone exposure [32]. CT-based detection
of osteosclerosis in suspicious jaw lesions without exposed bone may
assist in diagnosing Stage 3 BRONJ [33].
In conclusion, this study shows that 19 of 20 patients with Stage 2 or
3 BRONJ, most of whom had responded poorly to 1–4 weeks of treat-
ment with common antibiotics, achieved controlled or completely
healed status with or without surgery, after a maximum of ten weeks
on STFX. We also found that half our patients were affected by
recently-updated BRONJ staging criteria [12], suggesting that infection
statusmay bemore important than exposed bone status in determining
appropriate treatment for BRONJ patients. We also found four BRONJ
patients who presented with persistent paranasal sinusitis, suggesting
that maxillary BRONJ should be considered in the differential diagnosis
of BP patients who exhibit persistent paranasal sinusitis.
Aweakness of this study is that due to ethical concerns and the prior
existence of treatment guidelines for BRONJ [10–11], it was not possible
to include a control group of untreated BRONJ patients. In addition, no
non-BRONJ patients were characterized for bacterial species.
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